Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - “ANLOTINIB HYDROCHLORIDE CAPSULES” OBTAINED APPROVAL FOR THE FIFTH INDICATION2022.04.19
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2022.04.14
-
NEXT DAY DISCLOSURE RETURN2022.04.11
-
VOLUNTARY ANNOUNCEMENT INNOVATIVE DRUG "TQ-B3525" WAS INCLUDED IN THE LIST OF BREAKTHROUGH THERAPY DRUGS BY CDE2022.04.08
-
NEXT DAY DISCLOSURE RETURN2022.04.07
-
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF CATEGORY I NEW DRUG "TQC2938" INJECTION2022.04.07
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 20222022.04.01
-
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER, 20212022.03.31